Abstract
Immunotherapy has revolutionized treatment of cancers and autoimmune diseases. Bucking the trend, however, is type 1 diabetes (T1D), although it is one of best understood autoimmune diseases and individuals at genetic risk are identifiable with high certainty. Here we review the major obstacles associated with pan-B-cell-depletion using rituximab (RTX) and discuss the notion that B cell-directed therapy may be most effective as a preventive measure. We suggest that it will be more productive to aim at identifying and targeting autoreactive B cells rather than making adjustments to pan-B cell depletion and that non-conventional alternative therapies such as antibody blockade of FasL to bolster IL-10-producing Breg cells, which work successfully in mice, should be considered.
Original language | English (US) |
---|---|
Pages (from-to) | 213-219 |
Number of pages | 7 |
Journal | Discovery Medicine |
Volume | 21 |
Issue number | 115 |
State | Published - 2016 |
ASJC Scopus subject areas
- General Medicine